Table 3. CMML: patient characteristics and correlation with SRSF2 mutation status.
| variables | SRSF2 MUT(n = 14) | SRSF2 WT (n = 42) | P |
|---|---|---|---|
| Sex (female/male) | 4/10 | 15/27 | > 0.05 |
| Age (years) | 66.7 (25–82) | 62.4 (36–94) | > 0.05 |
| WHO subtypes | |||
| CMML-1 | 10 | 33 | > 0.05 |
| CMML-2 | 4 | 9 | |
| FAB subtypes | |||
| CMML-MD | 2 | 10 | > 0.05 |
| CMML-MP | 12 | 32 | |
| CPSS | |||
| low risk | 2 | 4 | |
| intermediate-1 risk | 7 | 30 | > 0.05 |
| intermediate- 2 risk | 5 | 7 | |
| high risk | 0 | 1 | |
| BM Blast (%) | 3.13 ± 1.7 | 3.04 ± 1.8 | > 0.05 |
| PB Blast (%) | 3.13 ± 1.7 | 3.18 ± 1.87 | > 0.05 |
| WBC (×109/L) | 36.1 ± 17.9 | 33.0 ± 13.1 | > 0.05 |
| HB (g/L) | 98.4 ± 16.7 | 94.4 ± 11.5 | > 0.05 |
| BPC (×109/L) | 225.6 ± 116.3 | 222.4 ± 135.8 | > 0.05 |
| Mono (×109/L) | 4.58 ± 3.1 | 3.2 ± 1.08 | > 0.05 |
| Mono (%) | 12.8 ± 3.38 | 15.1 ± 4.82 | > 0.05 |
| CSF3R mutation | 0/10 | 4/42 | < 0.001 |
| SETBP1 mutation | 2/14 | 1/42 | > 0.05 |
CMML, chronic myelomonocytic leukemia; WHO, World Health Organization; FAB, French, American and Britain; CMML-MD, CMML-myelodysplastic; CMML-MD, CMML- myeloproliferative; MUT, mutated; WT, wild type; CPSS, CMML Prognostic Scoring System; PB Blast, blast cell count of peripheral blood; BM Blast, blast cell count of bone marrow; WBC, white blood cell; HB, hemoglobin; BPC, blood platelet cell; Mono, monocyte.